- NLS Pharmaceutics Ltd. shareholders approved the merger with Kadimastem and related proposals at an Extraordinary General Meeting held on **September 29, 2025**, removing the final corporate hurdle prior to closing.  **[1783036_0001213900-25-093387_ea025937501ex99-1_nlspharma.htm:0]** 
- The combined company will be named **NewCelX Ltd.** and is expected to trade on Nasdaq under the ticker **"NCEL"**, subject to final Nasdaq approval.  **[1783036_0001213900-25-093387_ea025937501ex99-1_nlspharma.htm:0]** 
- Upon closing, Kadimastem shareholders will own **84.4%** of the combined company, and NLS shareholders will own **15.6%**.  **[1783036_0001213900-25-093387_ea025937501ex99-1_nlspharma.htm:0]** 
- The merger creates a diversified pipeline, uniting Kadimastem’s advanced cell therapy programs with NLS’s CNS small-molecule expertise.  **[1783036_0001213900-25-093387_ea025937501ex99-1_nlspharma.htm:0]**

NLS Pharmaceutics Shareholders Approve Merger with Kadimastem

- **NLS Pharmaceutics shareholders approved the merger with Kadimastem Ltd.** and all related proposals at an Extraordinary General Meeting held on **September 29, 2025**, clearing the final corporate milestone for the merger.  **[1783036_20250930IO86758:0]** 
- The combined company will be named **NewCelX Ltd.** and is expected to trade on Nasdaq under the ticker **"NCEL"**.  **[1783036_20250930IO86758:0]** 
- Upon closing, **Kadimastem shareholders will own 84.4%** of the combined company, while **NLS shareholders will own 15.6%**.  **[1783036_20250930IO86758:0]** 
- The new leadership team will include **Ronen Twito as Executive Chairman and Chief Executive Officer** and **Prof. Michel Revel as Chief Scientific Officer and Director**.  **[1783036_20250930IO86758:0]** 
- The merger creates a company with a **diversified pipeline**, uniting Kadimastem's advanced cell therapy programs with NLS's CNS small-molecule expertise.  **[1783036_20250930IO86758:0]** **[1783036_20250930IO86758:1]**

NLS Pharmaceutics (NLSP)